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SUMMARY
Obsessive-compulsive disorder (OCD) is characterized by intrusive
thoughts (obsessions) and repetiti ve mental acts or behaviours
(compulsions) . For many years, it was considered a rather
uncommon condition, caused by unconscious conflict, and somewhat
resistant to treatment. In recent decades, however, it has
emerged that OCD is a highly prevalent disorder, mediated by
particular neuroanatomical circuits (e.g. striatal pathways) and
neurochemical systems (e.g. the serotonin system), and responsive
to treatment with serotonin reuptake inhibitors (SRIs) .
Nevertheless, many questions remain; about the specificity of
neuroanatomical findings to OCD, about the role of the multiple
serotonin (5-HT) receptor subtypes (e.g. 5-HT10)' and about the
appropriate pharmacotherapy for patients resistent to SRI
treatment? In a series of studies, 1) the neuroanatomy of OCD was
assessed by means of magnetic resonance imaging and
neuropsychological testing, 2) the neurochemistry of OCD was
assessed by means of functional brain imaging after administration
of a 5-HT10 agonist, and 3) the pharmacotherapy of OCD was
explored in a series of treatment-refractory OCD and OCD spectrum
disorder patients using SRI augmentation with a dopamine blocker.
Although no significant difference was found in the volume of the
caudate in women with OCD and controls, there was a significant
correlation between caudate volume and neuropsychological
dysfunction in patients, consistent with evidence of striatal
involvement in OCD. Functional imaging demonstrated behavioural
heterogeneity, but brain-behaviour correlations were positive,
consistent with preclinical evidence of a role for the 5-HTlD
receptor in the mediation of OCD. Finally, preliminary treatment
findings with dopamine blocker augmentation of a SRI were
promising, consistent with preclinical understandings of the
interactions between the dopamine and serotonin systems. Although
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oeD is a complex disorder, a number of future research avenues
hold promise for providing a thorough delineation of its
pathogenesis.
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OPSOMMING
Obsessief-kompulsiewe steuring (OKS) word gekenmerk deur
indringende gedagtes (obsessies) en herhalende gedagtes of gedrag
(kompulsies). Vir baie jare is dit beskou as 'n redelik seldsame
toestand wat veroorsaak word deur onbewustelike konflik, en wat
in 'n mate teen behandeling weerstandig is. Meer onlangs het dit
egter na vore getree as 'n toestand wat baie dikwels voorkom, wat
deur spesifieke neuroanatomiese siklusse (bv. striatale bane) en
neurochemiese sisteme (bv. die serotonien-sisteem) teweeg gebring
word, en wat op behandeling met serotonien heropname inhibeerders
(SHIs) reageer. Nogtans is daar steeds baie vrae; oor die
spesifisiteit van neuroanatomiese bevindinge vir OKS, oor die rol
van die veelvuldige serotonien (5-HT) reseptor subtipes (bv. 5-
HT1D), en oor die toepaslike farmakoterapie vir pasiënte wat
weerstandig is vir SHI behandeling. In' n reeks van
navorsingstudies, is 1.) die neuroanatomie van OKS deur middel
van magnetiese resonans beelding en neurosielkundige toetse
ondersoek, 2. ) die neurochemie van OKS deur middel van
funksionele breinbeelding na toediening van 'n 5-HT1D agonis
bepaal, en 3.) die farmakoterapie van OKS in 'n reeks van
behandelingsweerstandige OKS en OKS-spektrum steuring pasiënte -
waar gebruik gemaak is van SHI aanvulling met 'n dopamien-blokker
- ondersoek. Alhoewel daar geen beduidende verskil in die volume
van die caudata in vroue met OKS en kontroles gevind is nie, was
daar 'n beduidende korrelasie tussen die caudata volume en
neurosielkundige wanfunksionering in pasiënte, in ooreenstemming
met striatale betrokkenheid in OKS. Funksionele beelding het
positief, in
demonstreer, maar
ooreenstemming met
brein-gedrag
pre-kliniese
heterogeneïteit
korrelasies was
in gedrag
bewyse vir 'n rol vir die 5-HT1D reseptor in die bemiddeling van
OKS. Ten laaste, voorlopige behandelingsbevindinge oor dopamien-
blokker aanvulling van 'n SHI is belowend, in ooreenstemming met
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die pre-kliniese begrip van die interaksies tussen die doparnien-
en serotoniensisteme. Alhoewel OKS 'n komplekse steuring is, is
daar talle toekomstige navorsingsrigtings wat belofte inhou vir
die deeglike uiteensetting van die patogenese daarvan.
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1. INTRODUCTION: THE PHENOMENOLOGYAND NEUROBIOLOGYOF OCD
Obsessive-compulsive disorder (OCD) has long been considered a
rather uncommon condition, caused by unconscious conflict, and
somewhat refractory to treatment. In recent decades, however, a
paradigm shift has occurred, and OCD is now viewed as one of the
most prevalent and disabling of psychiatric disorders, mediated by
specific neuronal circuits and neurochemical systems, and
responsive to certain pharmacotherapeutic and psychotherapeutic
interventions. This chapter provides the background for the
studies undertaken here, by reviewing the definition and diagnosis
of OCD, its epidemiology and impact, and its neurobiology.
1.1. Definition and Diagnosis
1.1.1. Obsessive-Compulsive Disorder
Obsessions are recurrent and persistent thoughts, impulses, or
images that the person typically regards as intrusive and
inappropriate (American Psychiatric Association, 1994).
Characteristically they increase levels of anxiety. An example is
the mother who is horrified by a recurrent image of herself
stabbing her new-born child, or the boy who is distressed by
repeated thoughts that he will be contaminated if he comes into
contact with dirt.
Compulsions are repetiti ve behaviours or mental acts that the
person feels driven to perform in response to an obsession, or
according to rules that must be followed rigidly (American
Psychiatric Association, 1994). Characteristically they
15
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temporarily diminish levels of anxiety. The mother with
aggressive obsessions may, for example, act to prevent the
stabbing by repeatedly checking that her kitchen knives are locked
away. Similarly, the boy with contamination obsessions may
repeatedly wash his hands to reduce distress about contact with
dirt.
While various habits may be present in normal people, obsessions
and compulsions in oeD cause marked distress or interfere
significantly with academic, occupational, or social function.
People with oeD are typically aware that symptoms are excessive or
unreasonable, but note that they are simply unable to resist these
repetitive thoughts and actions. A range of obsessions and
compulsions may be present in anyone patient (TABLE 1.1), and
these symptoms may also evolve over time with one set of
obsessions and compulsions replacing another (Rasmussen and
Tsuang, 1986; Swedo et al, 1989a).
The diagnostic criteria of the Diagnostic and Statistical Manual
of Mental Disorders (DSM) (TABLE 1.2) are invariably used in
current research on OeD, including the series of studies described
herein. These criteria, most recently updated on the basis of
extensive field research (Foa and Kozak, 1995) , clearly
distinguish OeD from lay concepts of "obsessive love" or
"obsessive neatness", as well as from other psychiatric disorders,
so allowing for rigorous and reliable diagnosis.
1.1.2. Obsessive-Compulsive Spectrum Disorders
Advances in the field of obsessive-compulsive disorder have led
also to increased attention to a series of possibly related
conditions, the so-called oeD spectrum disorders (Jenike, 1989;
16
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Hollander, 1993; McElroy et al, 1994; Yaryura-Tobias and
Neziroglu, 1997). While this spectrum can be defined in various
ways, a consistent theme in the literature has been the presence
of phenomenological and neurobiological overlaps between OCD and
disorders such as Tourette's syndrome (TS), body dysmorphic
disorder (BOD), hypochondriasis and trichotillomania (TTM) (Stein
and Hollander, 1993).
Nevertheless, the characterization of various disorders as OCD
related remains contentious, with some authors warning against
premature and overinclusive classifications Rasmussen, 1994).
Certainly there are considerable differences in the phenomenology
of the various putative OCD spectrum disorders. For example,
although unwanted repetitive motor symptoms are characteristic of
both OCD and trichotillomania (hair-pulling), in the latter
disorder there do not appear to be preceding obsessions. Other
phenomenological features also differ; for example,
trichotillomania appears considerably more common in women than
men (Christenson et al, 1991).
On the other hand, the idea that OCD and putative OCD spectrum
disorders are in someway related would seem to be a useful
heuristic both in clinical practice (where anti-OCD medication,
for example, may be effective in a range of conditions) and in
research (where similar mechanisms may be found to mediate diverse
disorders) . There has been a gradual accumulation of
neurobiological data suggesting a number of different, but
partially overlapping, approaches to this spectrum (Stein, 2000).
Indeed, the notion of an OCD spectrum begs the question of the
dimension along which the various conditions differ. Freud and
subsequent psychoanalysts contrasted obsessive-compulsive
neurosis, obsessive-compulsive character, and normal obsessive-
compulsive defenses (Stein and Stone, 1997). Some contemporary
17
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clinicians have suggested that obsessive-compulsive disorders lie
on the spectrum of affective disorders (McElroy et al, 1994).
Others have, however, emphasized the contrast between OCD (where
insight is usually retained) and psychotic disorders where insight
is usually lost) (Klein, 1993).
As the neurobiology of OCD and of putative OCD spectrum disorders
is increasingly understood it may be possible to begin to resolve
some of these questions. In the series of studies that comprise
this thesis, in addition to using healthy controls, patients with
trichotillomania are at times used as psychiatric controls. The
rationale is to provide a way of simultaneously assessing the
specificity of the neurobiology of OCD, and also contributing to
understanding the psychobiology of one of the putative OCD
spectrum disorders.
1.2. Epidemiology and Impact
1.2.1. Community Surveys
The Epidemiological
definitive study of
Catchment Area
the prevalence
(ECA) study was
of OCD using a
the first
structured
diagnostic instrument based on DSM diagnostic criteria. The ECA
found that OCD was the fourth most common psychiatric disorder,
present in 2-3% of the population (Karno et al, 1988). The
disorder had a roughly equal male to female ratio, and was present
equally in all socioeconomic groups.
Earlier, less systematic studies, had suggested that OCD was a
rather uncommon disorder. Furthermore, the interview procedure
used in the ECA study may have led to a degree of overestimation
18
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of prevalence. Nevertheless, it is now generally accepted that in
the past OCD prevalence has been significantly underestimated,
partly because patients frequently do not inform clinicians of
their symptoms (Hollander et al, 1997).
Another limitation of the ECA study is that work was done in the
developed world and in a single country. However, a cross-
national community survey based on the methodology of the ECA was
subsequently undertaken (Weissman et al, 1996). There was a
surprizingly uniform prevalence of OCD in both the developed and
developing world. These data strongly suggest that the
pathogenesis of OCD involves universal rather than culture-
specific psychobiological mechanisms (Stein and Rapoport, 1996).
2.2 Morbidity
In recent years, there has been growing awareness of the morbidity
of OCD and its substantial negative impact on quality of life
(Stein et al, 2000a). The term "quality of life" has both
subj ecti ve elements, as well as obj ecti ve components (role
functioning, living conditions) (Katschnig et al, 1997) .
Furthermore, the construct of QOL covers a range of different
domains, including family and social relations, scholastic and
work functioning, financial and health status, and living
situation.
One of the most remarkable datasets demonstrating the negative
impact of OCD is the Global Burden of Disease study undertaken by
the World Bank and the World Health Organization (WHO) (Murray and
Lopez, 1996). One measure employed by this study was the DALY -
disability adjusted life year. Of the 10 most disabling medical
19
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conditions worldwide, 5 are neuropsychiatric disorders, and one of
these (the 10th most disabling condition) is OCD.
Studies using epidemiological and clinical data are consistent
with the general tenor of the World Bank study. Dupont and
colleagues (1995), for example, estimated the annual costs of OCD
on the basis of data collected in the Epidemiological Catchment
Area (ECA) study. They calculated that reduced or lost
productivity from OCD was $5.9 billion a year in the United States
in 1990 - 70.4% of OCD's total economic costs. Leon et al (1995)
also highlighted the burden of OCD by focusing on unemployment and
disability findings contained in the ECA dataset.
Two parallel surveys of
organizations in South African
obsessive-compulsive consumer
(Stein et al, 1996) and the United
States (Hollander et al, 1997) similarly demonstrate the enormous
costs of OCD. Al though arguably limited by ascertainment bias,
the United States survey found a surprisingly long mean time from
onset of symptoms to appropriate treatment of 17 years.
Inappropriate outpatient treatment was estimated to cost $2
billion a year.
A number of clinical studies have emphasized the burden of OCD
across different domains, including instrumental role functioning
(work, school, and homemaking). Koran et al (1996) noted that
unemployment was twice as high in their sample of medication-free
OCD outpatients as in the general population, and that subjects'
mean scores for role limitations due to emotional problems, social
functioning and mental health were all below the 25th percentile.
Similarly, in their survey of work eligible OCD patients, Eisen et
al (2000) found that 32% had severe impairment in their ability to
work, and that similar frequencies were found at I-year and 2-year
follow-up.
20
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Domains other than instrumental and social functioning are also
affected by OCD. Several recent studies, for example, have
emphasized the disruption to families caused by OCD. The ECA
survey found that OCD subjects had higher rates of divorce and
separation than subjects without OCD (Karno et al, 1988)
symptoms often intrude on family life, and conversely
members may become involved in rituals (Emmelkamp et al,
Calvocoressi et al, 1995; Shafran et al, 1995; Black
1998a) .
OCD
family
1990;
et al,
1.3. Neurobiology
1.3.1. Neuroanatomy
1.3.1.1. Evidence for Cortico-Striatal Mediation of OCD
The earliest evidence that OCD had a specific anatomical basis
emerged during the encephalitic pandemic early this century.
Patients with post-encephalitic parkinsonism demonstrated
involuntary movements as well as obsessive-compulsive symptoms.
At post-mortem, brain pathology included basal ganglia lesions
(van Economo, 1931; Cheyette and Cummings, 1995). Certainly, this
early clinical evidence is consistent with modern understandings
of the role of cortico-striatal-thalamic-cortical (CSTC) loops in
the development, maintenance, and selection of motoric and
cognitive procedural strategies (Cummings, 1993).
A subsequent literature has demonstrated that many patients with
neurological conditions involving the basal ganglia, such as
Tourette's syndrome (Hollander et al,1989), Sydenham's chorea
21
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(Swedo et aI, 1989b), and Huntington's disease (Cummings and
Cunningham, 1992), may have co-morbid OCD. Conversely, patients
with OCD may have comorbid tics (Pitman et aI, 1987), or increased
involuntary movements
(Hollander et al, 1990;
ganglia pathology.
on neurological soft sign examination
Bihari et al, 1991), suggestive of basal
Occasionally patients with frontal lobe lesions present with OCD
symptoms, and OCD patients may show evidence of frontal lobe
impairment on electrophysiological studies (Khanna, 1988; Ames et
aI, 1994). Furthermore, magnetic resonance imaging (MRI) studies
have demonstrated frontal abnormalities in OCD (Garber et aI,
1989; Grachev et al,1998; Szeszko et al, 1999). Finally, surgical
lesions to frontal-striatal pathways may result in improvement in
OCD symptoms in refractory patients (Martuza et aI, 1990; Baer et
al, 1995).
Brain imaging studies provide the most important evidence of
cortico-striatal involvement in OCD. An early study indicated
that patients with OCD had reduced volume of the basal ganglia on
computed tomograph (CT) (Luxenberg et aI, 1989), although not all
subsequent volumetric studies have been consistent (Kellner et aI,
1991; Scarone et aI, 1992) (TABLE 1.3). Functional imaging
studies have, however, often demonstrated hyperactivity in
orbitofrontal cortex, anterior cingulate, and caudate nucleus;
further increase in these structures during exposure to feared
stimuli; and decreased activity after treatment (Rauch and Baxter,
1998) (TABLE 1.4-1.6). This patterns of findings differs notably
from that in other anxiety disorders (TABLE 1.7).
Innovative recent research in brain imaging in OCD has employed
novel methodologies and populations. For example, N-acetyl
aspartate levels may represent a measure of neuronal density, and
have been found reduced in two studies of OCD (Ebert et aI, 1997;
22
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Bartha et al, 1998) .Rosenberg and colleagues have published a
series of intriguing reports on brain imaging in pediatric
OCD,further emphasizing the role of CSTC circuits in OCD(Rosenberg
and Keshavan, 1998).
1.3.1.2. Conceptualizing CSTC Mediation of OCD
The development, maintenance, and selection of motoric and
cognitive procedural strategies mediated by CSTC circuits has been
given various terms including the habit system (Mishkin and Petri,
1984), response set (Robbins and Brown, 1990),and procedural
mobilization (Saint-Cyr, 1990) . Certainly, some form of
malfunctioning feedback or feedforward circuit might well explain
the repetitive nature of OCD symptoms. Furthermore, the basal
ganglia may be a repository for repetitive motor programmes, akin
to the repetitive behavioural sequences seen in OCD. It is as if
there is excessive release of such sequences as a consequence of
basal ganglia pathology (Wise and Rapoport,1989).
Baxter and colleagues have pointed out that the different CSTC
circuits have both a "direct" and an "indirect" pathway (Saxena et
al, 1998). The direct pathway facilitates striatal-thalamic
outflow, perhaps promoting the execution of procedural strategies.
In contrast, the indirect pathway inhibits thalamic activity,
perhaps allowing the cortex to respond to different stimuli and to
shift sets. In OCD, it may be postulated that there is
hyperacti vat ion of the direct pathway relative to the indirect
pathway.
Of the different CSTC circuits, the one that is arguably most
central to OCD is the ventral cognitive circuit, involving
anterior and lateral orbitofrontal cortex,ventromedial caudate,
23
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and dorsomedial nuclei of the thalamus. This system appears to
play a particularly important role in response inhibition,
particularly in relation to socioemotional and contextual cues
(Rauch and Baxter, 1998) . Indeed, on neuropsychogical
testing, patients with OCD demonstrate executive dysfunction, which
then has a negative impact on immediate nonverbal memory(Savage et
al, 1999).
Rauch and colleagues have shown that during brain imaging of an
implicit sequence learning task, normal controls show striatal
activation, but patients with OCD instead appear to recruit medial
temporal regions (Rauch et aL,1997). These latter regions are
typically involved in conscious cognitive-affective processing;
thus, whereas normals are able to process procedural strategies
outside of awareness, in OCD there instead appears to be intrusion
of information and emotion into consciousness.
A "striatal topography" model of OCD spectrum disorders suggests
that whereas the ventral cognitive system is involved in OCD, in
Tourette's syndrome (TS) and perhaps trichotillomania (O'Sullivan
et aI., 1997), there is rather involvement of the sensorimotor
cortex and putamen (Rauch and Baxter, 1998). On the other hand,
there is also evidence that OCD patients have involvement of the
range of different CSTC circuits (Rosenberg and Keshavan, 1998),
and it is possible rather that specific projection fields or cell
types are involved in specific kinds of symptoms. Certainly,
further work is necessary to delineate precisely the contribution
of CSTC circuits to OCD and to OCD spectrum disorders.
24
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1.3.1.3. Mechanisms Underlying CSTC Pathology in OCD
How does damage to CSTC circuits occur in primary OCD (OCD that is
not secondary to an obvious neurological lesion)? Non-specific
injury has long been hypothesized in OCD, With an early study
reporting an increasing incidence of birth trauma in OCD (Capstick
and Seldrup, 1977). Interestingly, the basal ganglia are
especially vulnerable to prenatal and perinatal hypoxic-ischemic
injury (Hyde and Weinberger, 1995). Disruption of striatal
circuitry is also seen after social deprivation during development
(Martin et al,1991).
In the last few years, a more specific neuroimmunological
hypothesis of OCD has gained steady ground. After noting the high
incidence of OCD symptoms in Sydenham' s chorea, Swedo and
colleagues began to explore patients who presented with OCD
symptoms and/or tics in the aftermath of Streptococcal infection,
a condition they have termed pediatric autoimmune neuropsychiatric
disorder associated with streptococcus (PANDAS) (Swedo et al,
1998) Their description of 50 cases with this picture suggests
that autoimmune mechanisms may lead to disruption of CSTC
circuits, and so to obsessive-compulsive symptoms in at least a
subset of OCD patients.
Additional
demonstration that
findings from this
patients with
group
PANDAS
include
respond
the
to
recent
immunomodulatory interventions such as plasma exchange and
intravenous immunoglobulin (Perlmutter et aI, 1999). Although
they have been unable to show that penicillin prophylaxis prevents
OCD, given that penicillin administration did not in fact prevent
streptococcal infection further studies with a more effective
prophylactic agent are required (Garvey et aI, 1999).
25
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What remains unclear is the extent to which Streptococcal
infection is important in OCD patients in general. A number of
interesting recent papers have contributed to this question by
focusing on neuroimmunological abnormalities in OCD. Abnormal
auto-antibodies, as well as range of less specific
neuroimmunological dysfunctions, have been found in OCD (Black et
al, 1998b; Marazziti et al, 1999; Mittleman et al, 1997).
Of particular interest in this regard, the B lymphocyte antigen
08/17, a marker for susceptibility to auto-immune complications in
the aftermath of Streptococcal infection, appears increased in
patients with OCD (Swedo et aI, 1997; Murphy et aI, 1997; Chapman
et al, 1998). Further work is, however, necessary to determine
whether this finding is specific to OCD;D8/17 expression was, for
example, also increased in autism (Hollander et aI, 1999).
1.3.2. Neurochemistry
1.3.2.1. Serotonin and Dopamine
Early anecdotal reports that OCD responded to treatment with a
predominantly serotonergic reuptake inhibitor, clomipramine
(Fernandez-Cordoba and Lopez-Ibor Alina, 1967) were the first
evidence that the serotonin neurotransmitter system might play a
role in OCD. Subsequent investigation demonstrated that OCD
responded to clomipramine, but not to desipramine, a predominantly
noradrenergic reuptake inhibitor, a finding that differentiates
OCD from many other psychiatric disorders,which respond to a range
of antidepressants (Zohar and Insel, 1987). More recently,
clinical trials of selective serotonin reuptake inhibitors (SSRIs)
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have invariably shown efficacy in the treatment of OCD (Greist et
al,1995; Stein et al, 1995a).
Recent research has provided additional evidence that the
serotonin system plays an important role in OCD. First, in at
least some studies, a subset of patients with OCD is found to have
elevated cerebrospinal fluid (CSF)levels of the serotonin
metaboli te 5-hydroxyindoleacetic acid (5-HIAA) (Zohar and Insel,
1987), and these levels may fall during successful treatment with
a SRI (Thoren et al, 198Oa) . Second, at least some groups of
researchers have found that administration of the serotonin
agonist, m-ch1orophenylpiperazine, results in exacerbation of OCD
symptoms in a subset of patients with OCD (Zohar et aI, 1987;
Hollander et aI, 1992a). Such a response is no longer seen after
treatment with clomipramine or a SSRI (Zohar et al, 1998;
Hollander et al, 1991).
Nevertheless, other
elevated CSF 5-HIAA,
patients with OCD do not appear to have
show no symptom exacerbation after mCPP, or
do not respond to treatment with SRIs.While some of these findings
may reflect methodological limitations of the relevant research,
another explanation of the data is that neurochemical systems
other than serotonin also playa role in OCD. The fact that tics
are common in OCD (Pitman et aI, 1987), and that OCD symptoms are
frequent in patients
1993), suggests that
symptoms.
with Touret te' s syndrome (Hollander et al,
the dopamine system may also mediate OCD
Indeed, serotonin and dopamine are known to have significant
functional interactions, and both pre-clinical and clinical
findings provide support for the hypothesis that dopamine is also
involved in OCD (Goodman et al,1990). Administration of dopamine
agonists may result in stereotypies
compulsive behaviours in humans
in animals and in increased
(Frye and Arnold, 1981;
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Borcherding et al, 1990). Patients with OCD and co-morbid tics
who fail to respond to an SRI may respond to the combination of a
SRI and a dopamine blocker (McDougle et al, 1994).
Additional neurochemical systems also appear to contribute to the
mediation of OCD symptoms. Administration of the opiate
antagonist, naloxone, for example, may exacerbate OCD symptoms
(Insel and Pickar, 1983). CSF studies of vasopressin, arginine,
oxytocin, and somatostatin in OCD have led some authors to suggest
that these neuropeptides may also be implicated in the disorder
(Altemus et al,1992; Leekman et al, 1994). The fact that OCD
often begins at the time of pregnancy suggests that hormonal
factors may also play a role (Neziroglu et al, 1992). Clearly
further work is necessary in order to elucidate fully the
neurochemical underpinnings of OCD.
1.3.2.2. Functional Polymorphisms of Monoamine Genes
The importance of monoamine neurotransmitters in OCD,taken
together with growing evidence from family studies that inherited
factors contribute to the pathogenesis of OCD (Pauls et al, 1986),
one avenue of recent research has been to investigate functional
polymorphisms of the serotonin and dopamine systems, as well as of
other possibly relevant neurochemical systems in this disorder.
Early studies provided some evidence to suggest that polymorphisms
of the serotonin transporter protein gene (5-HTTP) might contribute
to OCD (McDougle et al, 1998;Bengel et al, 1999). Notably, there
is an association between the 1/1 and lis polymorphism of this
gene and higher serotonin (5-HT) blood levels (Hanna et al,
1998),and 5-HT transporter binding (as assessed by 3H-paroxetine
binding to platelet membranes) has been found decreased in OCD.
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Nevertheless, in an
Afrikaner population
(Kinnear et al, in
polymorphisms in the
attempt to replicate this work in
of South Africa, we were unable to
press) , consistent with a view
5-HTTP gene may account for only a
the
do so
that
small
portion of the variance in predicting OCD.
There are now also several findings indicating that dopamine
system genetic polymorphisms may playa role in OCD. Two studies
have found an increased number of the 7 repeat allele of the DRD4
gene in patients with tics (Cruz et al, 1993; Billett et al, 1998).
There may also be other differences in dopamine polymorphisms in
patients with and without tics (Nicolini et al, 1996). While
several studies on various genetic findings in OCD have been
inconsistent or negative (Stein et al, 2000), data on genetic
differences between OCD patients with and without tics is
promising insofar as it supports the literature on differences in
phenomenology and treatment response in these two OCD groups.
1.3. 3. Integration of Neuroanatomy and Neurochemistry
An immediate question is that of the relationship between the
neurochemical considerations reviewed here and the neoroanatomical
research discussed earlier. It is noteworthy that the striatum
has significant serotonergic and dopaminergic innervation.
Furthermore, after administration of the serotonin agonist, mCPP,
there is increased cerebral blood flow in the frontal region in
those OCD patients who demonstrate symptom exacerbation(Hollander
et al, 1995), but not in other subjects (Hott Pian et al, 1998),
perhaps suggesting a link between CTSC hyperactivity, serotonergic
activation, and OCD symptoms.
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Conversely, as mentioned earlier, treatment of OCD with a SRI
results in a significant decrease in pre-frontal/orbito-frontal
and caudate activity on functional brain imaging (Rauch and
Baxter, 1998). Furthermore, working with paediatric OCD,
Rosenberg and colleagues have noted decreased serotonin synthesis
in ventral prefrontal cortex and caudate (Rosenberg et aI, 1998),
and caudate glutamatergic changes after SSRI treatment (Moore et
aI, 1998). Such work illustrates how the combination of
neurochemical and neuroanatomical methodologies is able to advance
an integrated approach to the neurobiology of OCD.
In addition, recent studies have begun to explore functional
imaging predictors of response to treatment in OCD. Increased
prefrontal metablism has previously been asociated with worse
response to clomipramine (Swedo et aI, 1989d). However, Brody et
al (1998) reported that while increased left OFC cortex metabolism
at baseline did correlate with worse outcome after medication, it
correlated with greater improvement after behaviour therapy. The
underlying mechanisms which explain these kinds of correlations
are currently unclear.
1.3.4. Neurobiology of Putative OCD Spectrum Disorders
Another question that emerges from a review of the neuroanatomy
and neurochemistry of OCD is whether the systems apparently
responsible for the mediation of OCD are also important in the
putative OCD spectrum disorders. The amount of information
available to address this issue varies, however,
disorder; some have been well-researched,
continues to be a paucity of data.
from disorder to
in others there
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Tourette's syndrome (TS) (Tourette's disorder) is perhaps the best
researched of the putative oeD spectrum disorders. oeD and TS
appear to have not only important phenomenological overlap, but
also significant neurobiological intersection; eSTe circuits play
a crucial role in TS, auto-immune mechanisms may be involved,
serotonergic and dopaminergic systems are important, and there
appears to be significant familial and genetic overlap with oeD
(Hyde and Weinberger, 1995; Stein, 2000).
In trichotillomania,
neurobiological data.
on the other hand, there is only limited
A structural imaging study suggested that
the caudate is not involved, but that left putamen may be smaller
in trichotillomania than in controls (0' Sullivan et al, 1997).
Given evidence of putamen abnormalities in TS, it is tempting to
suggest that both TS and trichotillomania are characterized by
predominantly motoric symptoms whereas OeD and other spectrum
disorders may involve the caudate and more cognitive symptoms
(TABLE 1.8).
A number of studies have explored neuropsychological aspects of
trichotillomania. In general, these have attempted to demonstrate
similarities in the neuropsychology of oeD and trichotillomania
and evidence of cortico-striatal involvement in both these
disorders.
Rettew et al (1991) compared trichotillomania, OCl)patients, and
controls on a neuropsychological battery which included the Stylus
Maze and the Money Road Map test. Trichotillomania patients had
significantly more errors than normal controls on two subtests of
the Stylus Maze, a test of visual-spatial memory, while oeD
patients differed significantly from normals on one subtest. The
authors concluded that differences between trichotillomania
patients and controls on the Stylus Maze were consistent with
spatial processing difficulties in this disorder.
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Keuthen and colleagues (1996) found group differences between
trichotillomania patients and normal controls in the Odd Man Out
Test, a measure of ability to maintain mental set, and on the Rey-
Osterreith Complex Figures Test immediate-recall, a test of
nonverbal memory. While there were no group differences on the
Rey-Osterreith Complex Figures Test copy score, a test of
visuospatial function, dysfunction on the Odd Man Out Test was
found for the stimuli of shapes but not letters. The authors
wondered whether this finding reflected greater difficulty in
maintaining a mental set when dealing with shapes, which are less
likely to be subject to verbal mediation strategies.
Coetzer and Stein (1999) compared neuropsychological functioning
in females with trichotillomania, OCD, and normal controls.
While, there were no significant differences between the three
groups on any of the measures studied, exploratory t-tests
indicated that the combined OCD and TTM group differed
significantly from normal controls in accuracy and planning on the
Rey-Osterreith copy score. Again it is possible to speculate that
disruption of visual-spatial coordination and sequencing tasks may
reflect damage to cortico-striatal pathways in these conditions.
Nevertheless, it seems that to date neuropsychology research
findings have been too inconsistent to clearly support such a
conclusion.
On functional imaging patients with trichotillomania were found to
have increased cerebellar and right superior parietal glucose
metabolic rates compared to normal controls (Swedo et al, 1991).
These authors also found that anterior cingulate and orbi tal-
frontal metabolism correlated negatively with clomipramine
response, a result they previously found in OCD. Increased
orbital-frontal metabolism may conceivably comprise a compensatory
response in both disorders.
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In terms of the pathogenesis of CSTC damage in the putative OCD
spectrum disorders, the neuroimmunology of conditions other than
TS has also received little attention. Swedo et al (1992) have,
however, suggested that hair-pulling may develop in the context of
Streptococcal infection. Stein et al (1997) have documented a
case of hair-pulling associated with Sydenham's chorea. However,
it is currently unclear how important auto-immune mechanisms are
in general samples of hair-pulling patients.
In a series of fascinating studies, Rapoport and colleagues showed
that clomipramine was superior to desipramine in a range of
repetitive symptoms other than OCD. These symptoms included hair-
pulling (Swedo et al,1989c) as well as a range of other
stereotypic behaviours (Leonard et al, 1991; Gordon et al, 1992;
Castellanos et aI, 1996). Nevertheless, the data on SRIs in hair-
pulling have been inconsistent, with a number of studies
indicating loss of response during SRI treatment (Pollard et aI,
1991), or lack of efficacy (O'Sullivan et aL,1999). Similarly,
mCPP challenges result in different behavioural and neuroendocrine
responses in OCD and trichotillomania (Stein et aI, 1995b).
As noted earlier, there is increasing evidence that dopamine plays
a role in OCD and putative OCD spectrum disorders (Goodman et aI,
1990), perhaps particularly in those with a marked motoric
component. There is some preliminary data that dopamine also
plays a role in trichotillomania. A recent report noted
exacerbation of hair-pulling by methylphenidate in a series of
children(Martin et aI, 1998). Furthermore, preliminary open data
suggests that augmentation of SRIs with classical antipsychotics
(dopamine blockers) may be useful in the treatment of hair-pulling
(Stein and Hollander, 1992; van Ameringen and Mancini, 1996).
Nevertheless, many questions about the neurobiology of the
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putative OCD spectrum disorders in general, and of
trichotillomania in particular, remain unanswered.
1.4. Questions for Further Study
Indeed, several
neurobiology of
questions are raised by this review of the
OCD for further study. In this thesis three
questions in particular are explored in more detail.
First, although there is good evidence that CSTC circuits are
involved in OCD, the nature and specificity of striatal volumetric
changes in OCD remains unclear. To date structural imaging
studies have been inconsistent, have seldom correlated imaging
findings with neuropsychological data, and have not included
psychiatric control groups (such as patients with a putative OCD
spectrum disorder). A study was undertaken of patients with OCD,
patients with trichotillomania, and normal controls using magnetic
resonance imaging (MRI) and neuropsychological testing. The study
rationale, methods, and results are detailed in Chapter Two.
Second, although it seems clear
involved in the mediation of OCD,
the role of specific serotonin
nature of their contribution in
that the serotonin system is
an immediate question regards
sub-receptors, as well as the
different regions of the CSTC
circui t. Given evidence from preclinical and clinical research
that orbitofrontal 5-HT1D receptors might be involved in mediating
OCD, using sumatriptan challenge together with single photon
emission tomography (SPECT). The study rationale,methods, and
results are detailed in Chapter Three.
Third,
and a
although SRIs are a first line of pharmacotherapy of OCD
number of putative OCD spectrum disorders,the question
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arises of the appropriate pharmacotherapy for OCD patients who are
refractory to these agents. Although there is a rationale for
using dopamine blockers, the classical antipsychotics run the risk
of important adverse events, including tardive dyskinesia. The
introduction of the atypical neuroleptics may, however, provide an
alternati ve option, and an augmentation
was therefore undertaken. The study
results are detailed in Chapter Four.
study using risperidone
rationale, methods, and
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2 . NEUROANATOMY OF OCD: A STUDY OF
IMAGING AND NEUROPSYCHOLOGICAL FUNCTION
MAGNETIC RESONANCE
2.1. Background
As noted in Chapter One, structural brain imaging studies in OCD
have been inconsistent. Both a computerized tomography study
(Luxenberg et aL, 1988) and a magnetic resonance imaging study
(Robinson et aI, 1995) found decreased volume of the caudate in
OCD patients, but there have also been a number of contrary
findings, including no change in volume (Kellner et al, 1991;
Stein et al, 1993),and increased volume (Scarone et al, 1992).
Furthermore, volumetric studies in OCD have not employed
psychiatric controls; there is particularly little evidence on
whether hypothesized abnormalities in OCD are specific, or are
also seen in putative OCD spectrum disorders such as
trichotillomania (TTM). A "striatal topography" model of OCD
(Rauch and Baxter, 1998) would suggest that the caudate is
involved in OCD, but that the putamen is involved in disorders
characterized by more motoric symptoms, such as Tourette's
syndrome (Singer et aI, 1993) and trichotillomania.
Finally, the question of whether structural and volumetric
findings in OCD are related to neuropsychological findings as not
been well explored. This question is important given an early
study demonstrating that only OCD patients with increased
neurological soft signs had increased ventricular-brain ratios
(VBR) (Stein et aI, 1993). Although the majority of OCD patients
do not have as many neurological soft signs as those assessed in
that study, the question of heterogeneity in OCD should not be
ignored.
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A magnetic resonance imaging (MRI) study was undertaken in OCD
patients, TTM psychiatric controls, and healthy normal controls.
All patients also received a neurological soft sign examination
and neuropsychological testing. In the clinical setting, TTM is
seen predominantly in women (Christenson et al, 1992), and the
study was therefore confined to females. The hypothesis was that
OCD patients and TTM patients would differ from controls on brain
imaging and neuropsychology.
2 . 2 . Methods
2.2.1. Subjects
13 OCD and 17 TTM adult patients were recruited from the OCD
Clinic of our tertiary hospital. All subj ects were interviewed
with the Structured Clinical Interview for the Diagnosis of Axis-I
Disorders (First et al, 1994). Patients met DSM-IV criteria
(American Psychiatric Association, 1994) for either OCD or TTM.
In the OCD patients, mean score on the Yale-Brown Obsessive-
Compulsive Scale (YBOCS) (Goodman et aL, 1989) was 25.4 + 6.9,
while in the TTM patients, mean score on the compulsions sub-scale
of the YBOCS was 9.3 + 1.6. Patients who met DSM-IV criteria for
maj or depression or a psychotic disorder, who had a history of
substance abuse, or who had a significant medical or neurological
disorder were excluded from the study. 12 healthy controls were
volunteers from the hospital's laboratory service. All subjects
gave informed written consent after the protocol had been accepted
by the University of Stellenbosch Medical School ethics committee.
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2.2.2. Magnetic Resonance Imaging
Magnetic resonance images were acquired with the South African
Medical Research Council's Elseint 0.5 T Gyrex V imager. Routine
spin-echo technique protocols were used to demonstrate the brain
parenchyma (Tl-weighted) and cerebrospinal fluid spaces (T2-
weighted). The following multislice sequences were performed: 1)
a Tl-weighted axial study (TR500/TElOms, slice width 6mm, slice
gap 3mm); 2) a T2-weighted axial study (TR2600/TE20,90ms, slice
width 6mm, slice gap 3mm); and 3) a Tl-weighted axial interleaved
study (TR500/TE30ms, slice width 3mm,slice gap Omm) of the basal
ganglia. All axial slices were planned parallel to the orbi to-
meatal line.
2.2.3. Volumetric Measures
Interleaved studies of the basal ganglia were examined using the
scanner's automatic region-of-interest procedure. On each slice
in which the caudate nucleus was clearly seen (typically 4
slices), this procedure was used to measure total brain volume,
right and left ventricular volume, and right and left caudate
volume. All scans were rated by two raters, who were blind to
patient diagnosis. The lentiform nucleus was not included in the
study as it soon became apparent that acceptable inter-rater
reliability for measurements of this structure was not possible on
our scans.
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2.2.4. Neuropsychology and Neurological Soft Signs
All subjects were assessed by a single neuropsychologist who was
blind to diagnosis. The assessment aimed to measure set-shifting
and visual-spatial function, which have previously been shown to
be impaired in OCD (Stein,1994) and TTM (Rettew et al, 1991). The
battery comprised 1) four subscales of the South African Weschler
Adult Intelligence Scale (comprehension, similarities, picture
completion, and block design) (Human Sciences Research Council,
1969), 2) the Stroop test (Stroop, 1935) and the Austin maze
(Walsh, 1985), 3) the Rey-Osterreith (Osterrieth, 1944; Lezak,
1983) and the Hooper Visual Organization (Hooper, 1983) tests. A
neurological soft sign examination previously studied in OCD and
TTM patients (Hollander et aI, 1990; Stein et aI, 1994a) was also
administered.
2.3. Results
2.3.1. Demographics
Mean ages and number of years of education of the 3 group were
calculated (TABLE 2.1). On analysis of variance (ANOVA), there
was a significant group difference (F=5.35, p=.009), with OCD
patients significantly older than both TTM patients (t=2.75,
p=.Ol) and healthy controls (t=2.84, p=.Ol). There was also a
significant difference in number of total years of education
(F=5.57, p=.008), with OCD patients having significantly less
education than healthy controls (t=3.65, p=.002).
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2.3.2. Volumetric Measures
Mean volumes of the caudate and lateral ventricles (expressed as a
percentage of total brain) and ventricular-brain ratio (VBR) were
calculated (Table One) Correlation of volumetric measures obtained
by the two readers for the right caudate (r=.99), left caudate
(r=.96), right ventricle (r=.97), left ventricle (r=.93), and VBR
(r=.94) were all significant (p<.OOl).
On analysis of variance (ANOVA) (three group comparison) there
were, however, no significant differences between groups on these
measures. Co-varying the ANOVA for age and for education yielded
the same negative result. Repeated measures analysis of variance
(RMANOVA) of bilateral measures was again not significant.
2.3.3. Correlations
Pearson's correlations were calculated in order to assess the
association between caudate and lateral ventricles (expressed as a
percentage of total brain) and ventricular-brain ratio and
neuropsychological and neurological soft sign measures in all
subj ects. Decreased left caudate volume was significantly
associated with decreased intelligence quotient (r=.37, p=. 04),
was significantly associated with increased impairment on the Rey-
Osterreith test (i.e. copy dysfunction) (r=.37, p=.04) and with
increased impairment in the Stroop test (i.e. difference between
time for reading with and without interference) (r=.41, p=.02), as
well as with total neurological soft signs (r=.33, p=.05). The
Rey-Osterreith test involves copying a complex figure and
therefore assesses visuoperceptual and visuomotor skills, while
the Stroop test involves reading words which are printed in a
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color other than the one spelled and therefore assesses ability to
shift set.
2.4. Discussion
The main findings of this study were that 1) adult women with OeD,
TTM, and healthy controls did not differ on MRI volumetric
measures of the caudate and ventricles and 2) decreased left
caudate volume correlated significantly with increased impairment
on some neuropsychological tests of set-shifting and of visual-
spatial function and with increased neurological soft signs.
Although perhaps disappointing, the failure to find group
differences here is consistent with previous research which has
shown no significant differences between women with OeD, TTM, and
normal controls on neurological soft signs (Stein et ai, 1994a).
It is notable that males are more likely than females to exhibit
developmental neurological dysfunction and this may account for
increased numbers of males with early-onset oeD (Swedo et aL,
1989a) . Females may develop oeD at other developmental periods
such as pregnancy, when different causal mechanisms are involved
(Neziroglu et al, 1992).
Another possibility is that the measures used in this study were
not sufficiently robust to obtain differences. The magnet of the
MRI used had relatively low power, and we were unable to measure
accurately structures such as the lenticular nucleus, although
putamen volume may be reduced in patients with trichotillomania
(O'Sullivan et ai, 1997) and other OeD spectrum disorders such as
Tourette's syndrome (Singer et ai, 1993).
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A final consideration is that abnormalities in the caudate in
patients with OCD and trichotillomania may not be homogenous.
Caudate volume has been reported to be reduced (Luxenberg et al,
1988; Robinson et al, 1995), normal (Kellner et al, 1991; Stein et
al, 1993) or increased (Scarone et al, 1992) in OCD. Different
pathogenic mechanisms may differentially affect caudate size - for
example, auto-immune reactions after streptococcal infection may
result in increased caudate volume (Giedd et al, 2000).
It is of interest that correlations were obtained between low left
caudate volume and increased neuropsychological dysfunction and
increased neurological soft signs. The hypothesis that the
caudate mediates OCD symptoms is supported by findings of a
relationship between neurological disorders involving the caudate
and these symptoms, and by caudate abnormalities on structural and
functional imaging studies of OCD (Wise and Rapoport, 1989).
Interestingly, a previous study found correlations between
dysfunction on the Stroop test and caudate metabolic activity on
positron emission tomography (Martinot, 1990). However, caudate
abnormalities are not necessarily specific to OCD, but rather may
be associated with a variety of psychopathological processes
(McHugh, 1989).
The relationship between OCD and TTM remains a subject for further
consideration and research (Swedo, 1993; Stein et al, 1994b). The
negative findings obtained here are clearly not the last word on
the subject. Future investigation, perhaps combining functional
brain imaging and neurochemical challenges, may be useful in
clarifying the role of the striatum not only in OCD, but also in
putative OCD spectrum disorders.
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3. NEUROCHEMISTRY OF OCD:
PHARMACOLOGICAL CHALLENGE
A STUDY COMBINING SPECT WITH
3. 1 . Background
As noted in Chapter One, evidence that serotonin plays a crucial
role in OCD includes pharmacotherapeutic dissection studies and
pharmacological challenge studies. High doses of serotonin
reuptake inhibitors administered for relatively long periods of
time have frequently (although not invariably) proven more
effective than equivalent regimes of noradrenergic reuptake
inhibitors in the treatment of OCD (Zohar and Insel, 1987; Leonard
et al, 1989). In addition, administration of serotonin agonists
such as m-chlorophenylpiperazine (mCPP) (Zohar et al, 1987;
Charney et al, 1988; Hollander et al, 1992; Piggott et al, 1992)
and sumatriptan (Zohar, 1993; Stern et al, 1998) have often
(although again not invariably) resulted in symptom exacerbation
or a relatively blunted neuroendocrine response in OCD patients,
and after treatment with serotonin reuptake inhibitors there is a
normalization of these responses (Zohar et al, 1988; Hollander et
al, 1991).
As also discussed earlier, evidence that cortico-striatal circuits
play an important role in underpinning OCD symptoms includes
studies of OCD in patients with neurological lesions of the basal
ganglia and frontal regions, research on involuntary movements in
OCD patients, investigation using structural and functional brain
imaging techniques, and treatment of refractory OCD patients with
neurosurgical disruption of cortico-striatal circuits. In
general, functional studies have shown increased baseline activity
in the orbito-frontal cortex and caudate, with increased activity
during behavioural provocation and decreased activity after
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treatment (Rauch and Baxter, 1998) . One study combined
pharmacological challenge and brain imaging techniques in a
determination of regional cerebral blood flow (rCBF) during mCPP
administration, and found that patients who demonstrated acute
exacerbation of OCD symptoms after mCPP administration had
relatively increased cortical perfusion (Hollander et aI, 1995).
In a second study mCPP did not lead to OCD symptom exacerbation,
and was accompanied by global reduction in rCBF (Hott-Pian et aI,
1998) .
Despi te these studies, much remains to be understood about the
neurobiology of OCD. One important question concerns the role of
specific serotonin sub-receptors in different brain regions in
OCD. Pre-clinical data has shown that the serotonin auto-receptor
may play a particularly important role in OCD. The serotonin
reuptake inhibitors (SRIs) are the only antidepressants that act
to desensitize the terminal serotonin auto-receptor (5-HT1B in
rats, 5-HT1D in guinea pig and humans) in rat hippocampus.
Furthermore, Blier and colleagues (El Mansari et aI, 1995) found
that treatment of guinea pigs with high doses of SSRIs for 8 weeks
resulted in desensitization of 5-HT1D receptors in orbitofrontal
cortex. Such desensitization was not, however, seen after only 3
weeks of treatment, after use of lower SSRI doses, or after
electroconvulsive therapy (ECT) - paralleling clinical findings in
OCD.
Interestingly, the main difference in the biochemical profile of
mCPP, which exacerbated OCD symptoms in some clinical studies, and
MK-212, which did not appear to do so (Bastani et al, 1990), is
that mCPP also has 5-HT1D agonist properties. A possible role for
this sub-receptor in OCD is supported by the reported exacerbation
of OCD symptoms shortly after administration of sumatriptan
(Zohar, 1993), an agent with specific 5-HT1D agonist effects
(Ferrari and Saxena, 1993; Peroutka, 1993).
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In this study, the functional role of the serotonin terminal auto-
receptor in OCD was investigated by undertaking single photon
emission computed tomography (SPECT) with technecium-99m
hexamethylpropylene amine oxime (Tc-99m HMPAO) during sumatriptan
and placebo challenge. The hypothesis was that, as in the case of
mCPP challenge (Hollander et ai, 1995), exacerbation of OCD
symptoms would be accompanied by increased cortical metabolism and
thus blood flow, and more specifically by increased activity in
the orbitofrontal-striatal circuit. There was also the
expectation that as in the case of mCPP challenge (Hollander et
ai, 1993), exacerbation of OCD symptoms would be associated with a
relatively poor response to subsequent treatment with SRls.
3. 2 . Methods
3.2.1. Subjects
A number of subjects (mean age 35.8 il 13.3 years, 10M/4F) were
recrui ted from the OCD Clinic of our tertiary hospital. All
subjects were interviewed with the Structured Clinical Interview
for the Diagnosis of Axis- I Disorders (First et al, 1994). All
subjects met DSM-IV diagnostic criteria for OCD and did not meet
criteria for co-morbid depression. Mean score on the Yale-Brown
Obsessive- Compulsive Scale (YBOCS) (Goodman et ai, 1989) was 24.2
± 3.4, while mean score on the Montgomery-Asberg Depression Rating
Scale (MADRS) was 11.2 + 3.8. Medication free interval prior to
the procedure was sufficiently long to ensure that level of
medication was zero. Subjects with significant medical or
All patientsneurological illness were excluded from the study.
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gave informed written consent after the protocol had been accepted
by the University of Stellenbosch Medical School ethics committee.
3.2.2. Sumatriptan Challenge
Sumatriptan (lOOmg orally) or placebo were administered at 8:30
a.m. according to a randomized counter-balanced double-blind
design. Obsessive-compulsive symptoms were rated by a trained
clinician at -30, 0, 30, 60, 90, 180, and 240 minutes using the
Clinician Challenge Obsessive-Compulsive Scale (Hollander et al,
1992a) . This is a clinician-rated scale for OCD severity. It
rates time, anxiety, and control over obsessions; and time,
anxiety, and control over compulsions. With appropriate training,
as was undertaken prior to this study, inter-rater reliability is
very high (Hollander et aI, 1992). After completion of each set
of challenges, this scale was used to determine whether OCD
symptoms had decreased, increased, or remained constant on the
sumatriptan day.
3.2.3. SPECT Imaging
To achieve a baseline state of cerebral metabolism, subjects were
placed supine in a quiet, dimly lit room for 30 minutes prior to
injection of the radiopharmaceutical. At 90 minutes after
administration of sumatriptan or placebo, 555 MBq (15 mCi) Tc-99m
HMPAO was injected in an arm vein through a previously placed
intravenous cannula. The baseline state was continued for 10
minutes after injection, whereafter SPECT imaging commenced. SPECT
imaging of the brain was performed with the subject's head
supported by a head rest, using a dual detector gamma camera
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(Elscint, Helix) equipped with a pair of fanbeam collimators. A
laser alignment system was used to ensure accurate and
reproducible positioning of the patient's head. Data were
acquired in the step-and-shoot mode, using a 360 degree circular
orbit, with the detectors of the gamma camera as close as possible
to the subject's head. The height of the imaging table and
distance of the camera detectors from the centre of the camera
were noted for each subject and the same measurements were used
for the second study. Data were acquired in a 128 x 128 image
matrix in 3 degree steps at 15 seconds per step.
3.2.4. SPEeT Analysis
Data were reconstructed by filtered backprojection, using a Metz
(5, 14) filter. The Chang method was used for attenuation
correction. Thirty-two transaxial tomographic slices, with a
slice thickness of 1 pixel, were reconstructed parallel to a line
drawn from the inferior aspect of the frontal lobe through the
middle of the cerebellum on a sagittal slice at mid-cerebellar
level. This line approximates the orbito-meatal line. Using these
internal landmarks for generating the transaxial slices ensured
reproducible and comparable slicing of the two studies performed
on each subject. A set of 16 coronal slices (perpendicular to the
angle of the transaxial slice) and 16 sagittal slices were also
generated for each study.
Semi-quantitative analysis of the imaging data was performed using
a set of 278 cortical and sub-cortical regions-of-interest (ROl)
(139 ROl for each brain hemisphere), using the transaxial slices.
These ROl were placed as follows (FIGURE 1): 6 ROl for each
cerebellar hemisphere (on two different slices), 5 ROl for each
mesial temporal lobe, 2 for each anterior temporal lobe, and 6 for
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each lateral temporal lobe. The frontal lobes were caudo-
cranially divided into inferior frontal (below the level of the
thalami and basal ganglia), mid frontal (at the level of the
thalami and basal ganglia) and superior frontal (above the level
of the thalami and basal ganglia) regions. Each of these regions
was again subdivided antero-posteriorly into anterior, lateral and
posterior frontal regions. Two of the inferior frontal slices
were used for the placement of 4 anterior frontal, 6 lateral
frontal and 6 posterior frontal cortical ROlon each side. Three
mid- frontal slices were used for placing 6 anterior frontal, 9
lateral frontal and 9 posterior frontal cortical ROl pm each side.
Six contiguous slices were used for the placement of a total of 18
ROl (3 per slice) on each side of the anterior cingulate gyrus.
The rest of the ROl were placed in a similar fashion on the
inferior parietal and occipital cortex (single slice below the
level of the thalami and basal ganglia), mid-parietal and
occipi tal cortex (single slice at the level of the thalami and
basal ganglia) and superior parietal cortex (single slice above
the level of the thalami and basal ganglia). Two slices were used
for placing ROlon the primary visual cortex. Subcortical ROl
were placed on the caudate nucleus and putamen on each side, using
3 contiguous slices. Three contiguous slices were also used for
the bilateral placement of thalamic ROl.
With the exception of an irregular ROl used in the lateral
temporal region, all other ROl were rectangular. The rectangular
ROl were all of a 2 x 2 pixel size, with the exception of 6 ROlon
each side of the anterior cingulate (2 x 1 pixel size each) and
one ROlon each side of the lateral temporal cortex (5 x 2 pixel
size) and one on each side of the superior parietal cortex (5 x 2
pixel si ze) .
An automated computer algorithm was used to determine the counts
per pixel in each ROl. The counts per pixel of all ROl in a
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specific anatomic region (e.g. lateral temporal, inferior-
anterior frontal) were averaged to obtain the mean counts per
pixel for each anatomical region. A total of 23 anatomical
regions on each side of the brain were eventually available for
analysis
lateral),
(cerebellum, temporal cortex (anterior, mesial,
inferior frontal cortex (anterior, lateral,
and
and
posterior), mid frontal cortex (anterior, lateral, and posterior),
superior frontal cortex (anterior, lateral, and posterior),
anterior cingulate gyrus, inferior and mid occipital cortex,
primary visual cortex, caudate nucleus, putamen, and thalamus).
The mean counts per pixel for each anatomical region were
subsequently expressed as a ratio of the mean whole brain counts
(region-to-whole brain ratio) J as well as a ratio of the mean
cerebellar counts per pixel (region-to-cerebellar ratio). The
mean whole brain counts were determined according to the method
described by Harris et al (1994).
After placing the ROl, all ROl were stored as a template and
subsequently transferred to the transaxial slices of the second
study performed on that subject. All ROl were placed by a single
observer, who was blind to the challenged clinical status of
subjects.
3.2.5. Pharmacotherapy
Subsequent to scanning, subjects underwent treatment with a
selective serotonin reuptake inhibitor (SSRl) . 11 patients were
treated with citalopram, the most specific of the SSRls currently
available, for 12 weeks. Dosage was initiated at 20mg daily,
titrated upward by 20 mg every 2 weeks if the medication was
tolerated and if clinical response was inadequate. Obsessi ve-
compulsive symptoms were rated at 2 weekly intervals using the Y-
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SOCS and a Clinical Global Impressions (CGI) change score. Also
included in the analysis, however, were the results of the 3
remaining patients - one who was treated with sertraline 200mg for
12 wks after scanning, one who was treated with fluoxetine 60mg
for 12 wks after scanning, and one who was lost to follow-up but
who had previously been treated with sertraline 200mg for 12 wks.
3.2.6. Data Analysis
Data was transferred to a statistical package for analysis. To
minimize inflation of Type I errors, analysis focused a priori on
the oribitofrontal-striatal circuit. Thus, repeated measures
analysis of variance (RMANOVA) was undertaken with drug
(sumatriptan, placebo) as the between factor, while hemisphere
(left, right), anatomical area (orbitofrontal, basal ganglia,
thalamo-cingulate) , and anatomical regions were the within
factors. Post-hoc 2-tailed t-tests were then calculated.
Pearson's correlations were also conservatively 2-tailed. All
analyses were performed using the region-to-whole brain ratio and
the region-to-cerebellar ratio.
3.3. Results
3.3.1. Behavioural Response
Behavioural response to the sumatriptan challenge was
heterogenous. 4 patients experienced an exacerbation of symptoms,
4 patients experienced an improvement of symptoms, and 6 patients
experienced no change. Consistent with this finding, comparison
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of peak change in OCD symptoms after administration of sumatriptan
and placebo, with paired t-tests, revealed no significant
differences. There were no differences in behavioural response
(ratio of patients showing exacerbation, no change, or worsening)
between male and female patients.
3.3.2. SPECT Findings
RMANOVA showed no significant effect for drug, but did show a
significant hemisphere by anatomical area by anatomical regions by
drug effect (TSQ=7.85, F=3.77, df=2,25, p=.04), using the region-
to-whole brain ratio. This result remained significant when using
the region-to-cerebellar ratio (TSQ=7.59, F=3.65, df=2,25, p=.04).
On paired t-tests of anatomical areas using region-to-whole brain
ratio, there was a significant increase in right putamen activity
after sumatriptan in comparison with placebo (t=2.12, p=.05), and
a tendency towards increased activity in right thalamus (t=2.10,
p=. 06) . On paired t-tests of anatomical areas using region-to-
cerebellar ratio, there was a significant increase in right
thalamus activity (t=2.31, p =.04) after sumatriptan, and a
tendency towards increased activity in right caudate (t=1.94,
p=.07) and in left inferior-anterior frontal lobe (t=1.76, p=.10)
(FIGURE 2).
3.3.3. Correlation of Behavioural and SPECT Findings
On sumatriptan challenge, there was a significant association
between increase in OCD symptoms and decreased activity in some
frontal areas (using region-to-whole brain activity), namely the
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left inferior-posterior
posterior frontal area
frontal
(r=.58,
area (r=.55,
p=. 03) .
p=. 04)
There
OCD
was also
symptoms
p=. 02) .
andsignificant correlation between increase
increased activity in the right cerebellum
in
(r=.62, None
of these associations was present during placebo challenge.
3.3.4. Correlation of Pharmacotherapy and SPECT Findings
On sumatriptan challenge there was a significant association
between response to SSRI treatment (on the CGI) and activity in
certain brain areas (using region-to-whole brain activity).
Specifically, on sumatriptan challenge, decreased response to
treatment was associated with decreased activity in the right
inferior-posterior frontal area (r=.55, p=.04) and with increased
activity in the right putamen (r=.54, p=.05). On placebo
challenge, there was an association of decreased response to
treatment with decreased activity in the left inferior-lateral
frontal area (r=.56, p=.04) and with increased activity in the
right lateral temporal area (r=.63, p=. Ol) . These associations
remained when patients treated with SSRls other than citalopram
were excluded from the analysis (although one correlation, that of
decreased response to treatment with decreased inferior- lateral
frontal area on placebo challenge, no longer reached statistical
significance) .
3.3.5. Comparison of Patients with Symptom Relief and Symptom
Exacerbation
One way analysis of variance (ANOVA)was used to compare activity
in anatomical areas (using region-to-whole brain ratio) in
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patients with symptom exacerbation, no change, and symptom relief
after sumatriptan. With the sumatriptan challenge data, there was
a significant group difference in the right putamen (F=4.4, df=13,
p=.04) and superior parietal area (F=4.0, df=13, p=.05), and a
trend towards a significant difference in the left inferior-
anterior frontal area (F=2.8, df=13, p=.lO) and left cerebellum
(F=3.6, df=13, p=.06). Compared to patients with symptom relief
(Table 2), patients with symptom exacerbation had significantly
increased activity in the right putamen (t=2.57, p=.04) and
significantly decreased activity in the right inferior-anterior
frontal area (t=3.4l, p=.Ol). Using the placebo challenge data,
there was a significant group difference in the right cingulate
(F=4.0, df=13, p=.05), and a trend towards significance in the
left thalamus (F=3.3, df=13, p=.07) and right cerebellum (F=3.4,
df=13, p=.07). However, post-hoc t-tests did not reveal
significant differences in activity between patients with symptom
exacerbation and symptom relief. Finally, there was also a trend
towards a significant difference between groups in response to
treatment (F=3.0, df=13, p=.09). Compared to those with symptom
relief, patients with symptom exacerbation after sumatriptan had
significantly poorer response to treatment (t=2.78, p=.03).
3.4. Discussion
The main findings of this study were 1) that behavioural response
to sumatriptan challenge in OCD was heterogenous; 2) that on
sumatriptan challenge there was a significant association between
increase in OCD symptoms and decreased activity in some frontal
areas; 3) that there was an association between decreased activity
in an inferior frontal area and worse response to treatment with a
SSRI and also patients with symptom exacerbation after sumatriptan
had poorer response to treatment.
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While a number of previous studies of serotonin agonists in OCD
have shown exacerbation of symptoms after their administration
(Zohar et al, 1987; Hollander et al, 1992a), there has also been a
good deal of heterogeneity within studies (for example, only 50%
of patients in one study had exacerbation (Hollander et al,
1992a)) as well as inconsistency between studies (for example,
several studies have failed to find that oral mCPP exacerbates OCD
symptoms (Charney et al, 1988; Piggott et al, 1992; Goodman et al,
1995) ). While these inconsistencies may reflect methodological
difficulties with challenge studies, they may also indicate
variation in the underlying neurobiology of OCD. Certainly,
variation in behavioural response to serotonin agonists is
consistent with variation in response rate of OCD to treatment
with SSRls (about 50% in some studies). Indeed, there is a
growing body of literature on the heterogeneity of symptoms,
associated features, family history, and treatment response in OCD
(Baer, 1994). Furthermore, responses to serotonergic challenges
in OCD may also vary across gender (Hollander et al, 1992a).
It is currently unclear what the neurobiological basis for such
differences in behavioural response to serotonin agonists in OCD
is. One possibility is that neurochemicals other than serotonin
are particularly important in some subgroups of OCD patients (for
example, dopamine may play a crucial role in patients with
comorbid tics, or hormonal factors may determine differential
responses in males and females). Alternatively, differences in
compensatory processes to an underlying dysfunction may play a
role; Swedo et al (19890) for example, have suggested that on
functional imaging a subgroup of OCD patients with increased
baseline compensatory orbitofrontal activity can be demonstrated,
and that this pattern of activity predicts subsequent poor
responses to pharmacotherapy with a SRI. Certainly, a number of
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studies have replicated this predictive association (Brody et al,
1998; Saxena et al, 1999).
Along these lines, it is possible that sumatriptan challenge
resulted in increased activity in the terminal auto-receptor, with
subsequent decrease in compensatory frontal activity, and an
increase in OCD symptoms in a sub-group of challenged patients.
Conversely, ongoing pharmacotherapy with SSRIs seems to be
associated with desensitization of the serotonin terminal auto-
receptor (El Mansari et al, 1995), 5-HT neuronal activation, and
ultimately normalization of functional activity in orbitofrontal-
striatal circuits and improvement in OCD symptoms (Baxter et al,
1992; Insel, 1992; Swedo et al, 1989d).
Previous work (Hollander et al, 1993) and the data here indicate
that OCD patients who demonstrate behavioural exacerbation in
response to a serotonin agonist have poorer outcome during
treatment with a SSRI. Perhaps such patients have increased
baseline compensatory orbitofrontal activity and serotonergic
systems that are less able to respond to pharmacological
manipulation. Analysis of a larger sample would, however, be
necessary in order to reach definitive conclusions about sub-types
of OCD and their responses to sumatriptan challenge and to
subsequent pharmacotherapy (Stern et al, 1998).
The correlation between exacerbation of OCD symptoms and decreased
frontal activity was different from that which we had expected
given the previous finding of increased cortical flow in patients
with exacerbation of OCD symptoms after mCPP adminstration
(Hollander et al, 1995). Although sumatriptan may act on 5-HT1D
heteroreceptors, it is possible that sumatriptan differs from mCPP
in acting primarily as an agonist at pre-synaptic 5HT-1D
receptors, while mCPP has important effects at post-synaptic
serotonin receptors. There may, however, also be significant
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differences in the response of adjacent brain areas to behavioural
and pharmacological challenges. For example, Rauch et al (1994)
found that left anterior orbitofrontal cortex correlated
positively with oeD symptoms after behavioural provocation, while
left posterior orbitofrontal cortex correlated negatively with
such symptoms.
Additional work combining functional brain imaging with different
serotonergic pharmacological challenges will be necessary in order
to dissect fully the functional neuroanatomy of the serotonin
system in oeD. Studies using 5-HT1D agonists with greater blood-
brain penetration than sumatriptan may be particularly useful.
Given a recent report of sumatriptan induced panic attacks in
anxious patients (Loi et aI, 1996), the specificity of the
response to sumatriptan in different anxiety disorders as well as
in healthy controls requires investigation.
The findings here are, however, consistent with a growing body of
Li,terature pointing to the importance of the serotonin terminal
auto-receptor in oeD. While it is undoubtedly the case that too
narrow a focus on one neuroreceptor or another in oeD will result
in oversimplification (Goodman et aI, 1990), further attention to
the 5-HT1D receptor in oeD may be particularly fruitful. The
convergence of clinical and pre-clinical data on a possible role
for this receptor in oeD is noteworthy.
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4. PHARMACOTHERAPY OF OCD: A STUDY AUGMENTING SRI WITH A
DOPAMINE BLOCKER
4.1 Background
As noted in Chapter One, since early reports of the efficacy of
the serotonin reuptake inhibitor clomipramine in the treatment of
obsessive-compulsive disorder (OCD) (Fernandez-Cordoba and Lopez-
Ibor Alino, 1967), a range of research has confirmed the selective
value of the serotonin reuptake inhibitors in this disorder (Zohar
and Insel, 1987; Greist et al, 1995; Stein et al, 1995a) as well
as in some of the putative OCD spectrum disorders (Swedo et aI,
1989c; Leonard et al, 1991; Gordon et al, 1992; Castellanos et al,
1996; Hollander et al, 2000).
Nevertheless, serotonin reuptake inhibitors are effective in only
around 50-60% of patients with OCD (Greist et aI, 1995; Stein et
al, 1995a), and the response may be even less robust in certain
putative OCD spectrum disorders such as trichotillomania (Pollard
et aI, 1991; O'Sullivan et aI, 1999), suggesting that other
neurochemical systems may also be important in these conditions.
McDougle and colleagues (1994) reported that OCD patients
refractory to serotonin reuptake inhibitors may respond to
augmentation of these agents with classical neuroleptics,
particularly if tics are present. Similarly, this combination of
agents has been reported effective in trichotillomania (Stein and
Hollander, 1992; van Ameringen and Mancini, 1996) and Tourette' s
syndrome (Hawkridge et al, 1996).
These findings are consistent with a range of pre-clinical and
clinical evidence indicating that dopamine plays a role in OCD and
possibly related disorders such as Tourette's syndrome (Goodman et
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al, 1990; Hollander et al, 1992b). Furthermore, the recent
introduction of atypical neuroleptics with favorable adverse
effect profiles, such as risperidone, has encouraged the use of
augmentation strategies with these agents in the treatment of OCD
(Jacobsen, 1995; Kopala and Honer, 1994; Koran et al, 1999;
McDougle et al, 1995a; Saxena et al, 1996), as well as in the
treatment of trichotillomania (Jacobsen, 1995) and Tourette's
syndrome (Giakas, 1995).
Here we review data collected on patients who failed to respond to
a serotonin reuptake inhibitor, and who were treated with
risperidone augmentation.
4.2 Methods
Patient details are tabulated (TABLE 4.1). All patients received
at least 12 weeks of treatment of a SSRI at maximally tolerated
doses, before being given risperidone. Risperidone was initiated
at 1mg daily, and titrated up according to symptom response and
tolerabili ty. Patients were assessed after 4 weeks of
augmentation treatment using the Yale-Brown Obsessive Compulsive
Scale (Goodman et al, 1986) as well as with a Clinical Global
Impression (CGI) change score. Effect of treatment on these
measures was also tabulated (TABLE 4.1).
4.3. Results
Eight patients who met DSM-IV criteria for OCD had received
augmentation of serotonin reuptake inhibitors with risperidone.
None of these patients had tics or a history of tics. None of
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these patients met diagnostic criteria for schizotypal personality
disorder. After risperidone augmentation, three patients reported
very much or much improvement in OCD symptoms, one patient noted
minimal to much improvement, three patients had no change in
symptoms, and one patient was unable to tolerate side effects of
increased anxiety and irri tabili ty. Two of the three responders
(CGI change score < 2) elected to continue the medication, and
improvement has been maintained for 10 and 3 months respectively.
The patient with minimal to much response elected to discontinue
risperidone two months later after experiencing significant
"slowing down" of thought processes.
Five patients who met DSM-IV criteria for trichotillomania, but
not for OCD, had received augmentation of serotonin reuptake
inhibitors with risperidone. None of these patients had tics or a
history of tics. On this regime, three patients reported
significant clinical improvement, a fourth reported minimal to
much improvement, and a fifth patient experienced no change. Two
of the responders have maintained improvement for some months on
this regime, but a third elected to discontinue risperidone three
months later after noticing increased symptoms of depression.
Three patients who met DSM-IV criteria for Tourette' s syndrome,
and who had co-morbid OCD symptoms, had received augmentation of
serotonin reuptake inhibitors with risperidone. In one patient,
there was significant improvement of both tic and OCD symptoms
after addition of risperidone. However, after two months of
treatment, the patient noted dramatic worsening of mood, and the
risperidone was discontinued. In the second patient, OCD symptoms
were already fully controlled when risperidone was used in place
of pimozide.
OCD symptoms
patient, OCD
On this regime, the patient experienced no change in
and further improvement in tics. In the third
symptoms had shown some improvement on the
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combination of a SSRI and pimozide, and replacement of pimozide
with risperidone did not result in any further change.
4.4. Discussion
Given the
compared
evidence
advantageous adverse effect profile of risperidone
with classical neuroleptics (Chouinard et ai, 1993),
that this agent is similarly effective in the
augmentation of serotonin reuptake inhibitors in treatment
refractory OCD would have obvious clinical importance. A review
of a series of cases of patients with OCD, trichotillomania, and
Tourette's syndrome, suggests that in patients refractory to
treatment with serotonin reuptake inhibitors, risperidone
augmentation may indeed be effective for some within a relatively
short space of time. At the relatively low doses of risperidone
used extrapyramidal side effects were not problematic, but other
adverse effects such as increased depression did at times lead to
discontinuation of this agent.
Clearly there are significant limitations to the data presented
here. These include the limited sample size, and the lack of a
placebo-or dose-controlled treatment design. It might be argued
that increased duration of exposure to serotonin reuptake
inhibitors rather than risperidone augmentation was responsible
for clinical improvement, although in all patients duration of
monotherapy was at least 12 weeks. Alternatively, it is possible
that risperidone alone has anti-OCD effects, although there is
little data to suggest that neuroleptic monotherapy is effective
in this disorder (McDougle et ai, 1995b; Bruun and Budman, 1996;
Lombroso et al, 1995) . In addition, early response to
pharmacotherapy, perhaps particularly in trichotillomania (Pollard
et ai, 1991), is not always long-lasting. Nevertheless, data here
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is consistent with a very recently reported controlled trial of
risperidone in treatment-refractory oeD (McDougle et al, 2000).
It is theoretically possible that risperidone augmentation results
in increased blood levels of the serotonin reuptake inhibitor so
leading to a therapeutic response (Byerly and DeVane, 1996).
However, in their studies of neuroleptic augmentation, McDougle et
al (1994, 2000) found no relationship between serotonin reuptake
inhibitor blood level and treatment response. Furthermore,
response to the combination of a serotonin reuptake inhibitor and
an atypical antipsychotic is consistent with preclinical data
indicating involvement of both serotonergic and dopaminergic
systems in stereotyped movements (Goodman et al, 1990). In
addi tion, this finding is consistent with reports of the use of
serotonin reuptake inhibitors with classical antipsychotics in oeD
(McDougle et al, 1994), trichotillomania (Stein and Hollander,
1992; van Ameringen and Mancini, 1996), and Tourette's syndrome
(Hawkridge et al, 1996) as well as with previous anecodotal
reports of risperidone augmentation in these disorders (Kopala and
Honer, 1994; McDougle et al, 1994; Saxena et al, 1996; Jacobsen,
1995). As in this study, this previous literature has indicated
that the response to dopaminergic augmentation occurs relatively
quickly.
There are, however, also several anecdotal reports of exacerbation
of oeD symptoms by atypical neuroleptics (Hwang et al, 1993; Patel
and Tandon, 1993; Remington and Adams 1994). Experimental
administration of metergoline (Benkelfat et al, 1989), a 5-HT11/5-
HT2 antagonist, or of ritanserin (Ergovesi et al, 1992), a 5-HT2A12C
antagonist, during SRI treatment can reverse the therapeutic
effects of SRI treatment. It is similarly possible that clozapine
and risperidone, both of which are 5-HT2 antagonists, may on
occasion exacerbate oeD. In our patients, although risperidone
did not worsen obsessive-compulsive symptoms, a number of subjects
experienced increased depression after addition of this agent. 5-
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HT2/D2 affinity ratios are higher for clozapine than for
risperidone, perhaps accounting for differences in the effects of
these agents. Alternatively, there is evidence that particular
effects of combined serotonergic-dopaminergic blockade are
observed in only a narrow dose range (Kapur and Remington, 1996),
perhaps accounting for these apparently differences in the data.
In conclusion, additional research is necessary to determine the
indications for, and optimal dose and duration of, risperidone
and other atypical antipsychotics in the augmentation of serotonin
reuptake inhibitors in oeD and putative oeD spectrum disorders.
It is possible that this augmentation strategy may be most
effecti ve in patients with both oeD and tics (McDougle et al,
1994), although this has not clearly been shown here or elsewhere
(Saxena et al, 1996; McDougle et al, 2000) . Atypical
antipsychotic augmentation may also be useful in OCl) spectrum
disorders characterized by stereotypical kinds of symptoms.
Nevertheless, attention to the possible adverse affects of these
agents is also warranted.
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5. CONCLUSION: DIRECTIONS FOR FUTURE RESEARCH ON OBSESSIVE-
COMPULSIVE DISORDER
In this chapter the neuroanatomy, neurochemistry, and
pharmacotherapy of OCD are briefly reconsidered in light of the
studies in Chapters Two to Four, and areas that require future
research are addressed. In general, it would seem that future
work on OCD should make use of a range of neuroanatomic,
neurochemical, neurogenetic, and neuroimmunological data in order
to assess the variance contributed by multiple different factors
to the pathogenesis and outcome of this complex and heterogenous
disorder.
5.1. Neuroanatomy
In Chapter One, evidence that cortico-striatal-thalamic- cortical
(CSTC) circuits play a crucial role in mediating both OCD and
putative OCD spectrum disorders was outlined. In Chapter Two a
study of magnetic resonance imaging (MRI) in OCD patients,
trichotillomania patients, and healthy controls was described.
The study was unable to find a signficant group difference, and
potential methodological reasons for this were considered.
Indeed, despite the negative study described herein, there is no
reason to revise the hypothesis that OCD is mediated by CSTC
circuitry. Although the role of other circuits should not be
neglected in future work (Jenike et ai, 1996), there is a growing
realization of the importance of different CSTC loops in mediating
a range of psychiatric symptoms including those of OCD (Cummings,
1993) . In particular, striatal function has increasingly been
associated with the development, maintenance, and selection of
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motoric and cognitive procedural strategies. Cortico-striatal
dysfunction may result in inappropriate release of behaviours such
as washing, hoarding, and so on.
A crucial question for future research will be that of
ascertaining how putative damage to the CSTC circuits in OCD comes
about. The possibility that anti-striatal antibodies may play a
role has been strengthened by the description of the syndrome of
pediatric autoimmune neuropsychiatric disorder associated with
streptococcus (PANDAS) (Sweda et al, 1998). Such patients appear
to respond to immunomodulatory interventions such as plasma
exchange and intravenous immunoglobulin (Perlmutter et aI, 1999).
Notably, in PANDAS
symptom exacerbation,
(Giedd et al, 2000).
basal ganglia volumes are increased during
but decrease following symptom attenuation
This finding may explain the broad range of
findings in previous work, including the study described herein,
on basal ganglia volumes in OCD. Similarly, a previous study
found that structural brain imaging findings were crucially
dependent on neuropsychiatric sub-type of the disorder, with
increased ventricular-brain ratio correlating with increased
neurological soft signs (Stein et al, 1993). Thus, in exploring
the neuroanatomy of OCD in the future, it will be crucial to focus
on questions of heterogeneity, including differences in the timing
of the brain scan in relation to the development of the disorder.
Similarly, further exploration of differences and overlap in
neuroanatomical, neuroimmunological, and other factors in OCD and
OCD spectrum disorders may be useful. In a study of the B
lymphocyte antigen D8/17, a marker of susceptibility to developing
complications after Streptococcal infection, for example, our
group found that OCD patients differed from normal controls, but
that trichotillomania subjects did not (Niehaus et al, 1999). The
paucity of literature on structural brain imaging in some of the
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putative OCD spectrums disorders (such as trichotillomania, body
dysmorphic disorder, and hypochondriasis) is remarkable, and
presents an opportunity for further work.
5.2. Neurochemistry
In Chapter One, evidence that the serotonin system is crucial in
mediating OCD was described. In Chapter Three, preclinical
evidence that the 5-HT1D auto-receptor might play a particularly
important role was presented, and clinical data that were
consistent with this hypothesis were presented. Once again,
however, the heterogeneity of the findings was emphasized.
Clearly further work on specific 5-HT sub-receptors in OCD is
important (for example, using newly available radiopharmaceuticals
with affinity for specific 5-HT sub-receptor), and may well lead
to therapeutic advances. In addition to work on the 5-HT1D
receptor, the 5-HT2 receptor also deserves additional as a
potential locus for therapeutic agents (Delgado and Moreno, 1998).
Nevertheless, it should also be emphasized that despite frequent
discussion of the "serotonergic mediation of OCD", there is to
date little evidence that serotonergic dysfunction per se plays a
causal role in the disorder. The serotonin system is in close
interaction with many any other systems, and it is quite possible
that more primary lesions lie elsewhere.
Indeed, given recent advances in human genomics, a crucial next
step is to determine the role of various functional polymorphisms
in a range of different neurochemical systems in contributing to
OCD and putative OCD spectrum disorders. Indeed, recent work
confirms evidence from early family studies (Pauls et al, 1986)
that specific genetic factors can playa crucial role in OCD (De
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Marchi et al, 1998; Devor and Magee, 1999). There is also
preliminary polymorphism evidence underlining the validity of the
distinction between OCD patients with and without tics (Cruz et
al, 1993; Billett et al, 1998; Nicolini et al, 1996).
Nevertheless, there are also inconsistent and negative findings.
Data in Afrikaner OCD patients from our group, for example, has
not been consistent with work elsewhere (Niehaus et al, in press;
Kinnear et al, in press), suggesting either that previous findings
account for only a small percentage of the genetic variance in
OCD, or that there are significant ethnic differences in the
genetic mediation of OCD. An important milestone, however, was
the publication of a complete genome screen in TS, which yielded 2
suggestive regions (4q and 8p) (The Tourette Syndrome Association
International Consortium for Genetics, 1999). It is unlikely to
be long before similar work is published in OCD.
5.3. Pharmacotherapy
In Chapter One, the value of serotonin reuptake inhibitors (SRIs)
in OCD and putative OCD spectrum disorders was reviewed; the
introduction of these medications was clearly a significant
advance. Nevertheless, many patients are refractory to these
agents, and in Chapter Four data was presented to suggest the
potential value of augmentation of an SRI with an atypical
antipsychotic. These data suggest that additional studies on
other more recently available atypical antipsychotics be
undertaken, and that questions of optimal dose and duration be
addressed. Augmentation strategies using agents with other
mechanisms of action should also be explored (Cora-Locatelli et
al, 1998; McDougle et al, 1999).
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In addition, particularly given the small sample sizes of
available augmentation studies, a focus in future work on the
heterogeneity of OeD and on determining the value of augmentation
strategies for different sub-groups would seem valuable. It seems
clear that oeD patients with comorbid tics are less likely to
respond to SRls than patients without tics (McDougle et aI, 1993).
In contrast, early trials found no association between other
potential predictors such as age, sex, severity of OeD, and
duration of illness, and response to clomipramine (Thoren et aI,
1980b; De Vaugh-Geiss et al 1991).
Subsequent studies have not, however, been entirely consistent.
Predictors of non-response of OeD to SRls in some work have
included male gender (Steiner et aI, 1996), increased severity of
OeD (Alarcon et al, 1993), a longer (Alarcon et aI, 1993; Ravizza
et aI, 1995) or shorter (Steiner et aI, 1996) duration of illness.
A re-analysis of the multicentre clomipramine trial found that
those with the best chance of responding had onset at a later age
and were not significantly depressed (Ackerman et aI, 1994).
In a study of the citalopram data, we found only that subjects
with longer duration of OeD, more severe OeD symptoms, or previous
SSRI use were less likely to be responders in the citalopram trial
(Stein et al, submitted). In contrast, subj ects who received
higher medication doses for longer periods of time in the
citalopram trial were more likely to be responders. These points
are in some ways obvious; they do not advance an understanding of
the pathogenesis of OeD, but only underline the importance of
efforts to prevent the all to long lag between symptom onset and
clinical diagnosis of OeD (Hollander et aL, 1997; Stein et aL,
1996), and the potential value of appropriate psychoeducation for
people with oeD (Stein et aI, 1997; Stein et aI, in press).
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5.4 Combining Approaches
A flaw in the studies presented here is that we were unable to
study the same patients with different methodologies (MRI, SPECT,
08/17, etc). We have several times emphasized the heterogeneity
of OCD. In all likelihood, as in other complex psychiatric
disorders defined currently only by diagnostic convention, there
will turn out to be significantly different kinds of OCD mediated
in part by different factors. In our present state of relative
ignorance it seems that a "shotgun approach" in which a range of
different factors are assessed in multiple patients cannot be
avoided.
Of course there may be significant overlap in different factors;
genetic factors contribute to OCD and TS, CSTC dysfunction is seen
in both OCD and putative OCD spectrum disorders, and such
dysfunction may be caused by particular neurogenetic and
neuroimmunologial factors. On the other hand, there are likely to
be significant differences in underlying neurobiology between,
say, the child who develops OCD and tics immediately after
Streptococcal infection, the adolescent with a significant family
history of both OCD and TS who develops hoarding during
adolescence, and the women with no family history of OCD or tics
who develops compulsive washing during pregnancy.
In short, and in summary, there have been significant advances in
OCD; we now understand more about the neuroanatomy,
neurochemistry, and pharmacotherapy of OCD and the way in which
these overlap. At the same time, however, there are significant
gaps in our understanding; there is much that we do not know about
what appears to be a complex and somewhat heterogenous disorder,
and a good deal of future research will be necessary in order to
delineate its neurobiology more completely. The work undertaken
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herein is presented in the hope that it will help encourage such
research to proceed.
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TABLE 1.1 COMMON OBSESSIONS AND COMPULSIONS IN OCD
Obsession Compulsion
Contamination
Danger to self/others
Symmetry concerns
Blasphemy, morality
Saving concerns
Washing, cleaning
Checking locks, stove, switches
Lining up, straightening
Praying, confession
Hoarding
70
Stellenbosch University http://scholar.sun.ac.za
TABLE 1.2 DIAGNOSTIC CRITERIA FOR oen (adapted from DSM-IV)
A Either obsessions or compulsions: Obsessions as defined by (1),
(2), (3), and (4): (1) recurrent and persistent thoughts,
impulses, or images that are experienced, at some time during the
disturbance, as intrusive and inappropriate and that cause marked
anxiety or distress (2) the thoughts, impulses, or images are not
simply excessive worries about real-life problems (3) the person
attempts to ignore or suppress such thoughts, impulses, or images,
or to neutralize them with some other thought or action (4) the
person recognizes that the obsessional thoughts, impulses, or
images are a product of his or her own mind (not imposed from
without as in thought insertion) Compulsions as defined by (1) and
(2): (1) repetitive behaviors (e.g., hand washing, ordering,
checking) or mental acts (e.g., praying, counting, repeating words
silently) that the person feels driven to perform in response to
an obsession, or according to rules that must be applied rigidly
(2) the behaviors or mental acts are aimed at preventing or
reducing distress or preventing some dreaded event or situation;
however, these behaviors or mental acts either are not connected
in a realistic way with what they are designed to neutralize or
prevent or are clearly excessive
B. At some point during the course of the disorder, the person
has recognized that the obsessions or compulsions are excessive or
unreasonable.
C The obsessions or compulsions cause marked distress, are time
consuming (take more than 1 hour a day), or significantly
interfere with the person's normal routine, occupational (or
academic) functioning, or usual social activities or
relationships.
D. If another Axis I disorder is present, the content of the
obsessions or compulsions is not restricted to it.
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E. The disturbance is not due to the direct physiological effects
of a substance (e.g., a drug of abuse, a medication) or a general
medical condition.
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TABLE 1. 3 STRUCTURAL BRAIN IMAGING FINDINGS IN OCD
Study Modallty Flndlngs
Insel et al, 1983 CT No caudate differences
Behar et al, 1984 CT t ventricle:brain ratio (VBR)
Luxenberg et al, 1988 CT .!. caudate volume
Kellner et al, 1991 MRI No striatal differences
Scarone et al, 1992 MRI t R caudate volume
Stein et al, 1993 CT t VBR with t neurological soft
signs
Robinson et al, 1995 MRI .!. caudate volume
Jenike et al, 1996 MRI R caudate shift
Aylward et al, 1996 MRI No caudate differences
CT = computerized tomography
MRI magnetic resonance imaging
VBR = ventricular-brain ratio
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Study Modallty Bza i.ri Ac t.a v a cy
TABLE 1 . 4 FUNCTIONAL
RESTING STATE
Baxter et al, 1987
Baxter et al, 1988
Swedo et al, 1989
Nordahl et al, 1989
Benkelfat et al, 1990
Perani et al, 1995
Machlin et al, 1991
Rubin et al, 1992
Lopez-Ibor, 1995
BRAIN IMAGING FINDINGS IN OCD:
iL orbital gyrus, caudate
i orbitofrontal
i anterior cingulate
i orbitofrontal
i frontal, caudate, putamen
icingulate, lenticulate,
thalamus
i medial frontal
iorbitofrontal, ~ caudate
ibasal ganglia, hippocampus
PET
PET
PET
PET
PET
PET
SPEeT
SPEeT
SPEeT
PET = positron emission tomography
SPEeT = single photon emission tomography
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TABLE 1.5 FUNCTIONAL BRAIN IMAGING FINDINGS IN OCD:
SYMPTOMS PROVOCATION
Study Modal~ ty Caudate A/LOFC Pa z-aLa.rnbi.c
Rauch et al, 1994
McGuire et al, 1994
Breiter et al, 1996
PET
PET
PET
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
PET = positron emission tomography
A/LOFC = Anterior/lateral orbitofrontral cortex
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TABLE 1.6 FUNCTIONAL IMAGING FINDINGS IN CCD AND CCD
SPECTRUM: PRE/POST TREATMENT
Study Modall ty Treatment ,J,ACtlVlty
Baxter et al, PET Trazodone Caudate (? )
1997
Benkelfat et al, PET Clomipramine Orbitofronta1, caudate
1990
Hoehn-Saric et al, SPECT Fluoxetine Medial frontal
1991
Baxter et al, PET Fluoxetine/Behavioral Caudate
1992
Swedo et al, PET Mostly clomipramine Orbitofrontal
1992
Perani et al, PET SSRls Cingulate
1995
Mol1ina et al, SPECT Clomipramine Orbitofrontal, ant.
1995 cingulate, R caudate
Schwartz et al, PET Behavioral Caudate
1996
PET = positron emission tomography
SPECT = single photon emission computerized tomography
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TABLE 1.7 STRUCTURAL BRAIN IMAGING FINDINGS IN OTHER
ANXIETY DISORDERS
Study Daaqrio si.a Modall. ty Fl.ndl.ngs
Potts et al,
1994
Myslobodsky,
1995
Canive et al,
1997
Gurvitz et al,
1996
Bremner et al,
1995
Bremner et al,
1997
Schuff et al,
1997
Stein et al,
1997
Social MRI
Phobia
PTSD MRI
PTSD MRI
PTSD MRI
PTSD MRI
PTSD (child MRI
abuse)
PTSD MRI
PTSD (child MRI
abuse)
~basal ganglia volume (?)
tcavum septum pellucidum
tfocal white matter lesions
hippocampus volume negatively
correlated with symptom
severity
~R hippocampus (negatively
correlated with memory
deficits)
~ L hippocampus
~R hippocampus
~L hippocampus (negatively
correlated with symptom
severity)
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TABLE 1.8 STRUCTURAL
SPECTRUM DISORDERS
BRAIN IMAGING FINDINGS CCDIN
Study Dlagnosls Modallt Flndlngs
y
Peterson et al, 1993
Singer et al, 1993
Hyde et al, 1995
O'Sullivan et al,
1997
TS = Tourette's syndrome
TTM = trichotillomania
TS
TS
TS twin pairs
TTM
MRI
MRI
MRI
MRI
R lenticulate shift
R lenticulate shift
~ caudate volume
R putamen shift
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TABLE 2.1 COMPARISON OF MRI VOLUMES IN WOMEN WITH OCD,
TTM, AND HEALTHY CONTROLS
OCD
(n=13)
TTM
(n=17)
CONTROLS
(n=12)
ANOVA
Age 42.2 + 10.9 32.5 + 8.4 36.1 + 9.9 p=.03-
Education 12.9 + 1.7 14.1 + 1.7 15.6 + 1. p=.002- -
Right caudate 0.79 + 0.11 0.80 + 0.11 0.82 + 0.12 ns- -
Left caudate 0.78 + 0.07 0.82 + 0.18 0.85 + 0.07 ns- -
Right ventricle 0.64 + 0.19 0.75 + 0.26 0.62 + 0.20 ns- - -
Left ventricle 0.76 + 0.17 0.87 + 0.35 0.71 + 0.25 ns-
MRI magnetic resonance imaging
oeD obsessive-compulsive disorder
TTM trichotillomania
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TABLE 3.1 COMPARISON OF ACTIVITY IN REGIONS OF INTEREST
AFTER SUMATRIPTAN AND PLACEBO CHALLENGE (REGION-TO-WHOLE
BRAIN RATIO)
Sumatriptan
(n=14)
Placebo
(n=14)
p
Right Hemisphere
Cerebellum 1. 98 1. 99 ns
Temporal - Anterior 1.17 1. 21 ns
- Median 1. 28 1. 28 ns
- Lateral 1. 34 1. 34 ns
Frontal - Inferior-anterior 1. 53 1. 54 ns
-lateral 1. 60 1. 61 ns
-posterior 1. 54 1. 56 ns
- Medial-anterior 1. 50 1. 51 ns
-lateral 1. 64 1. 64 ns
-posterior 1. 56 1. 57 ns
- Superior-anterior 1. 52 1. 53 ns
-lateral 1. 64 1. 64 ns
-posterior 1. 62 1.64 ns
Cingulum 1. 61 1. 60 ns
Parietal - Inferior 1. 53 1. 50 ns
- Medial 1. 58 1. 56 ns
- Superior 1. 58 1. 57 ns
Occipital - Inferior 1. 41 1. 42 ns
- Medial 1. 38 1. 39 ns
- Superior 1.65 1. 63 ns
Thalamus 1.80 1. 74 .04
Caudate 1. 64 1.69 ns
Putamen 1. 59 1. 55 .07
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Left Hemisphere
Cerebellum 1. 96 1. 99 ns
Temporal - Anterior 1.19 1.18 ns
- Median 1. 32 1. 29 ns
- Lateral 1. 28 1. 27 ns
Frontal - Inferior-anterior 1. 53 1. 56 ns
-lateral 1. 59 1. 58 ns
-posterior 1. 55 1. 50 ns
- Medial-anterior 1. 51 1. 49 ns
-lateral 1. 66 1. 65 ns
-posterior 1. 57 1. 56 ns
- Superior-anterior 1. 53 1. 52 ns
-lateral 1. 62 1. 61 ns
-posterior 1. 64 1. 64 ns
Cingulum 1. 65 1. 62 ns
Parietal - Inferior 1. 53 1. 50 ns
- Medial 1. 53 1. 52 ns
- Superior 1. 55 1. 55 ns
Occipital - Inferior 1. 38 1. 42 ns
- Medial 1. 34 1. 32 ns
- Superior 1. 64 1. 63 ns
Thalamus 1. 78 1. 78 ns
Caudate 1. 70 1. 66 ns
Putamen 1. 56 1. 53 ns
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TABLE 4.1 RISPERIDONE AUGMENTATION OF SEROTONIN REUPTAKE
INHIBITORS (SRIs)
Sex Age Dx SRI trial YBOCS pre-
risperidone
Risperidone YBOCS post- CGI
trial risperidone
F 54 OCD Paroxetine 60mg 24 2mg daily 16 2
daily x 14 wks x 4 wks
F 28 OCD Paroxetine 60mg 28 1mg daily 28 4
daily x 12 wks x 1 wk
M 43 OCD Paroxetine 60mg 20 1mg daily 16 2.5
daily x 9 mnths x 4 wks
M 27 OCD Clomipramine 200mg 28 2mg daily 28 4
daily x 6 mnths x 4 wks
M 19 OCD Fluoxetine 40mg 28 1mg daily 29 4
daily x 12 wks x 4 wks
F 59 OCD Clomipramine 250mg 14 1mg daily 4 1
daily x 7 mnths x 4 wks
M 33 OCD Citalopram 60mg 18 1mg daily 8 1
daily x 3 mnths x 4 wks
F 40 OCD Clomipramine 250mg 18 1mg daily 18 4
daily x 9 mnths x 4 wks
F 22 TTM Clomipramine 200gm 5 1mg daily 3 2
daily x 8 mnths x 4 wks
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M 45 TTM Clomipramine 50mg 5 1mg daily 3 2.5
daily x 12 mnths x 4 wks
F 43 TTM Citalopram 40mg 8 1mg daily 8 4
daily x 36 mnths x 4 wks
F 31 TTM Clomipramine 175mg 8 1mg daily 4 2
daily x 12 wks x 4 wks
F 23 TTM Clomipramine 100mg 6 1mg daily 3 2
daily x 6 mnths x 4 wks
M 20 TS Citalopram 60mg 24 4mg daily 14 OCD - 2
daily x 10 mnths x 4 wks tics - 2
M 16 TS Fluoxetine 40mg 0 4mg daily 0 OCD - 4
plus pimozide 4mg x 4 wks tics - 2
daily x 12 mnths
M 24 TS Citalopram 60mg 20 3mg daily 20 OCD - 4
plus pimozide 8mg x 4 wks tics - 4
daily x 18 mnths
YBOCS=Yale-Brown Obsessive-Compulsive Scale (Compulsion scale only
in trichotillomania patients)
CGI=Clinical Global Impression Change Scale (l=very much improved,
2=much improved, 3=minimally improved, 4=no change)
TTM=trichotillomania
TS=Tourette's syndrome
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Figure 1: Cortical and sub-cortical regions-at-interest (Ral) on
transaxial slices.
Temporal ROl. 2 mealaI, 1 anterior
an 3 lataraJ on each side. Cerebellar ROl, 3 on each side
Inferior parietal ROl, 4 on each side.
Occipita) ROl, 3 on each aide.
Visual eonex ROl, 3 on each aide.
Superior parietal ROl, 4 on each side
Inferior frontal ROl, 2 anterior,
3 lateral and 3 posterior on each aide
Mid frontal ROl, 2 anterior, 3 lateral
and 3 posterior, on each side.
Cingulate gyrus ROl, 3 on each aide.
Basal ganglia ROl, 4 on Neh side.
Thalamic ROl, 2 on each side.
Superior frontal ROl, 2 anterior,
2 lateral and 2 posterior on each side
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FIGURE 2: EXAMPLE OF DIFFERENCES IN
IMAGING AFTER PLACEBO (TOP ROW) AND
ROW) SEEN IN ONE SUBJECT
ACTIVITY ON BRAIN
SUMATRIPTAN (BOTTOM
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